Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24258324 | 0.87 | SIRT2 (0.43) | NOS3NOS2GLSALDH1A1GAA | |
| SCHEMBL13185361 | 0.83 | NOS3 (0.47) | NOS3NOS2GLSALDH1A1GAA | |
| SCHEMBL10254409 | 0.81 | ADRB2 (0.56) | NOS3NOS2GLSALDH1A1GAA | |
| SCHEMBL21503646 | 0.81 | CYP2D6 (0.52) | NOS3NOS2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL2616106 | 0.80 | NOS3 (0.52) | NOS3NOS2GLSALDH1A1GAA | |
| SCHEMBL26913694 | 0.79 | NOS3 (0.47) | NOS3NOS2GLSALDH1A1GAA | |
| SCHEMBL13167405 | 0.79 | TRPV3 (0.45) | NOS3NOS2GLSALDH1A1GAA | |
| SCHEMBL2259096 | 0.75 | KDM1A (0.47) | NOS3NOS2ALDH1A1CYP3A4SIRT2 | |
| SCHEMBL10288360 | 0.75 | KDM1A (0.48) | GLSGAAL3MBTL1MBOAT4 | |
| SCHEMBL30471983 | 0.75 | KDM1A (0.48) | GLSGAAL3MBTL1MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | disclosed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | disclosed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | NOS3 3992/4885NOS2 4153/4885GLS 1606/4885 |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | PROKR1, PROKR2, GIPR | NOS3 3992/4885NOS2 4153/4885GLS 1606/4885 |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | NOS3 4317/4885NOS2 3606/4885GLS 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.